Erybraedin C

Erybraedin C

SCHEMBL29572548

CC(C)=CCc1cc2c(cc1O)OC[C@H]1c3ccc(O)c(CC=C(C)C)c3O[C@@H]21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 9/20 0.77
▸ HSD17B1 P14061 1/20 0.55
▸ ACHE P22303 1/20 0.45
▸ HSP90AA1 P07900 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phaseollidin SCHEMBL29349654 0.88 PTPN1 (0.77) PTPN1HSD17B1
Phaseollidin SCHEMBL1545850 0.88 PTPN1 (0.77) PTPN1HSD17B1
Erybreadin C SCHEMBL31237899 0.87 PTPN1 (1.00) PTPN1HSD17B1HSP90AA1
Erybraedin A SCHEMBL29572007 0.85 PTPN1 (0.76) PTPN1HSD17B1HSP90AA1
Calopocarpin SCHEMBL30659500 0.83 PTPN1 (0.69) PTPN1
Calopocarpin SCHEMBL29411831 0.83 PTPN1 (0.69) PTPN1
Erythribyssin L SCHEMBL31061391 0.82 HSD17B1 (0.57) PTPN1HSD17B1
SCHEMBL31237827 0.81 PTPN1 (0.73) PTPN1HSD17B1ACHE
SCHEMBL29572116 0.81 PTPN1 (0.88) PTPN1HSD17B1HSP90AA1
SCHEMBL29705706 0.80 PTPN1 (0.65) PTPN1HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3346842-B1 STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME NOVONESIS PLANT BIOSOLUTIONS AS (DK) 2026-03-25 — — EP claimed
US-11560342-B2 Bacillus isolates and uses thereof MONSANTO TECHNOLOGY, LLC (US) 2023-01-24 — — US claimed
US-20260146009-A1 Paenibacillus Isolates and Uses Thereof Novonesis Plant Biosolutions A/S (DK) 2026-05-28 — — US disclosed
US-12624333-B2 Stable inoculant compositions and methods for producing same NOVOZYMES BIOAG A/S (DK) 2026-05-12 — — US disclosed
US-12612342-B2 Paenibacillus isolates and uses thereof NOVOZYMES BIOAG A/S (DK) 2026-04-28 — — US disclosed
EP-4037457-B1 SEED TREATER WITH BAFFLES GUSTAFSON ENG SOLUTIONS LLC (US) 2026-04-22 — — EP disclosed
EP-3346842-B1 STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME NOVONESIS PLANT BIOSOLUTIONS AS (DK) 2026-03-25 — — EP disclosed
US-20260076287-A1 Devices For Use In Treating Seeds, And Related Methods GUSTAFSON ENGINEERED SOLUTIONS LLC 2026-03-19 — — US disclosed
US-20260053145-A1 PSEUDOMONAS ISOLATES AND USES THEREOF Novonesis Plant Biosolutions A/S 2026-02-26 — — US disclosed
EP-4658077-A2 PAENIBACILLUS ISOLATES AND USES THEREOF Novonesis Plant Biosolutions A/S (DK) 2025-12-10 — — EP disclosed
EP-3873188-B1 DEVICE AND METHOD OF TREATING SEEDS GUSTAFSON ENG SOLUTIONS LLC (US) 2025-12-03 — — EP disclosed
WO-2022208169-A1 PULSATILE PROTOCOLS FOR CANCER TREATMENT METHODS AND USES CLINICS OPERATIONS LIMITED (GB) 2022-10-06 — — WO disclosed
WO-2022207494-A1 3-(HETERO)ARYL-5-CHLORODIFLUOROMETHYL-1,2,4-OXADIAZOLE AS FUNGICIDE BAYER AKTIENGESELLSCHAFT (DE) 2022-10-06 — — WO disclosed
EP-4061969-A1 PAENIBACILLUS ISOLATES AND USES THEREOF Novozymes Bioag A/S (DK) 2022-09-28 — — EP disclosed
US-20220291237-A1 Gene Expression Inflammatory Age and Its Uses Edifice Health, Inc. (US) 2022-09-15 — — US disclosed
EP-4037457-A1 SEED TREATER WITH BAFFLES AND METHOD OF TREATING SEEDS USING SAME Monsanto Technology LLC (US) 2022-08-10 — — EP disclosed
US-20220240519-A1 MICROBIAL COMPOSITIONS AND METHODS MONSANTO TECHNOLOGY LLC (US) 2022-08-04 — — US disclosed
WO-2022125639-A1 MODIFIED PLANT-ASSOCIATED BACTERIA AND METHODS OF THEIR USE MONSANTO TECHNOLOGY LLC (US) 2022-06-16 — — WO disclosed
US-11317633-B2 Microbial compositions and methods MONSANTO TECHNOLOGY, LLC (US) 2022-05-03 — — US disclosed
EP-3634105-B1 SYSTEM AND METHOD FOR TREATING SEEDS MONSANTO TECHNOLOGY LLC (US) 2022-04-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260146009-A1 Paenibacillus Isolates and Uses Thereof FBL, NOP2, SPOUT1 PTPN1 1659/4885HSD17B1 3495/4885ACHE 4182/4885
US-12612342-B2 Paenibacillus isolates and uses thereof MASTL, NT5M, FBL PTPN1 1837/4885HSD17B1 4614/4885ACHE 4687/4885
US-12624333-B2 Stable inoculant compositions and methods for producing same UGDH, MGAM, SORD PTPN1 1849/4885HSD17B1 497/4885ACHE 794/4885
US-20260076287-A1 Devices For Use In Treating Seeds, And Related Methods BROX, TNF, CROCC PTPN1 800/4885HSD17B1 1006/4885ACHE 1183/4885
US-11560342-B2 Bacillus isolates and uses thereof BLVRB, BROX, GLB1 PTPN1 4068/4885HSD17B1 3514/4885ACHE 1569/4885
US-20260053145-A1 PSEUDOMONAS ISOLATES AND USES THEREOF MRPL21, MYB, PDGFRB PTPN1 1180/4885HSD17B1 4805/4885ACHE 3940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback